Tandem Diabetes Care Inc. (TNDM)

The total asset value of Tandem Diabetes Care Inc. (TNDM) stood at $ 1,125 Mln as on 31-Mar-23

The share price of Tandem Diabetes Care Inc. (TNDM) is $22.49 (NASDAQ) as of 07-Dec-2023 09:40 EST. Tandem Diabetes Care Inc. (TNDM) has given a return of -38.07% in the last 3 years.

Tandem Diabetes Care Inc. (TNDM) has a market capitalisation of $ 1,587 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of Tandem Diabetes Care Inc. (TNDM) is 6.25 times as on 02-Jun-2023, a 0.55% premium to its peers’ median range of 4.02 times.

Since, TTM earnings of Tandem Diabetes Care Inc. (TNDM) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tandem Diabetes Care Inc. (TNDM) and enter the required number of quantities and click on buy to purchase the shares of Tandem Diabetes Care Inc. (TNDM).

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

The CEO & director of Mr. John F. Sheridan. is Tandem Diabetes Care Inc. (TNDM), and CFO & Sr. VP is Ms. Leigh A. Vosseller.

The promoters of Tandem Diabetes Care Inc. (TNDM) have pledged 0% of the total equity as on Dec-22.

Some of the close peers are:

No, TTM profit after tax of Tandem Diabetes Care Inc. (TNDM) was $-204 Mln.